| Line |
Label |
Object Class |
Period Type |
Balance |
Report ElementName |
| 1 |
0001000 - Document - DEI |
Network |
* |
* |
http://www.veronapharma.com/role/Dei |
| 2 |
Implied Table |
Table |
* |
* |
implied:Table |
| 3 |
Document Information [Abstract] |
Abstract |
|
|
vrna:DocumentInformationAbstract |
| 4 |
Document Type |
Concept (Submission Type) |
For Period |
|
dei:DocumentType |
| 5 |
Entity Filer Category |
Concept (Filer Category) |
For Period |
|
dei:EntityFilerCategory |
| 6 |
Document Fiscal Year Focus |
Concept (Year) |
For Period |
|
dei:DocumentFiscalYearFocus |
| 7 |
Amendment Flag |
Concept (Yes/No) |
For Period |
|
dei:AmendmentFlag |
| 8 |
Document Period End Date |
Concept (Date) |
For Period |
|
dei:DocumentPeriodEndDate |
| 9 |
Document Fiscal Period Focus |
Concept (Fiscal Period) |
For Period |
|
dei:DocumentFiscalPeriodFocus |
| 10 |
Entity Registrant Name |
Concept (Text/String) |
For Period |
|
dei:EntityRegistrantName |
| 11 |
Entity Central Index Key |
Concept (CIK Number) |
For Period |
|
dei:EntityCentralIndexKey |
| 12 |
Current Fiscal Year End Date |
Concept (Month/Day) |
For Period |
|
dei:CurrentFiscalYearEndDate |
| 13 |
Entity Well-known Seasoned Issuer |
Concept (Yes/No) |
For Period |
|
dei:EntityWellKnownSeasonedIssuer |
| 14 |
Entity Current Reporting Status |
Concept (Yes/No) |
For Period |
|
dei:EntityCurrentReportingStatus |
| 15 |
Entity Emerging Growth Company |
Concept (Yes/No) |
For Period |
|
dei:EntityEmergingGrowthCompany |
| 16 |
Entity Ex Transition Period |
Concept (Yes/No) |
For Period |
|
dei:EntityExTransitionPeriod |
| 17 |
Entity Shell Company |
Concept (Yes/No) |
For Period |
|
dei:EntityShellCompany |
| 18 |
Number of shares outstanding (in shares) |
Concept (Shares) |
As Of |
|
dei:EntityCommonStockSharesOutstanding |
| 19 |
1001000 - Statement - CONSOLIDATED STATEMENT OF FINANCIAL POSITION |
Network |
* |
* |
http://www.veronapharma.com/role/ConsolidatedStatementOfFinancialPosition |
| 20 |
Implied Table |
Table |
* |
* |
implied:Table |
| 21 |
Statement of financial position [abstract] |
Abstract |
|
|
ifrs-full:StatementOfFinancialPositionAbstract |
| 22 |
Assets [abstract] |
Abstract |
|
|
ifrs-full:AssetsAbstract |
| 23 |
Non-current assets: |
Abstract |
|
|
ifrs-full:NoncurrentAssetsAbstract |
| 24 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 25 |
Intangible assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 26 |
Property, plant and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 27 |
Total non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 28 |
Current assets: |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 29 |
Prepayments and other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets |
| 30 |
Current tax receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentTaxAssetsCurrent |
| 31 |
Short term investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents |
| 32 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 33 |
Total current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 34 |
Total assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 35 |
EQUITY AND LIABILITIES |
Abstract |
|
|
ifrs-full:EquityAndLiabilitiesAbstract |
| 36 |
Capital and reserves attributable to equity holders: |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 37 |
Share capital |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 38 |
Share premium |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:SharePremium |
| 39 |
Share-based payment reserve |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ReserveOfSharebasedPayments |
| 40 |
Accumulated loss |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 41 |
Total equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 42 |
Current liabilities: |
Abstract |
|
|
ifrs-full:CurrentLiabilitiesAbstract |
| 43 |
Derivative financial instrument |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentDerivativeFinancialLiabilities |
| 44 |
Trade and other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 45 |
Tax payable—U.S. Operations |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentTaxLiabilitiesCurrent |
| 46 |
Total current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 47 |
Non-current liabilities: |
Abstract |
|
|
ifrs-full:NoncurrentLiabilitiesAbstract |
| 48 |
Assumed contingent obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 49 |
Deferred income |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredIncomeClassifiedAsNoncurrent |
| 50 |
Total non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 51 |
Total equity and liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAndLiabilities |
| 52 |
1002000 - Statement - CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME |
Network |
* |
* |
http://www.veronapharma.com/role/ConsolidatedStatementOfComprehensiveIncome |
| 53 |
Implied Table |
Table |
* |
* |
implied:Table |
| 54 |
Profit or loss [abstract] |
Abstract |
|
|
ifrs-full:IncomeStatementAbstract |
| 55 |
Research and development costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 56 |
General and administrative costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GeneralAndAdministrativeExpense |
| 57 |
Operating loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 58 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 59 |
Finance expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 60 |
Loss before taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 61 |
Taxation — credit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 62 |
Loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 63 |
Other comprehensive income / (loss): |
Abstract |
|
|
ifrs-full:OtherComprehensiveIncomeAbstract |
| 64 |
Exchange differences on translating foreign operations |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation |
| 65 |
Total comprehensive loss attributable to owners of the Company |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent |
| 66 |
Loss per ordinary share — basic and diluted (pence per share) |
Concept (Share) |
For Period |
|
ifrs-full:BasicAndDilutedEarningsLossPerShare |
| 67 |
1003000 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS |
Network |
* |
* |
http://www.veronapharma.com/role/ConsolidatedStatementOfCashFlows |
| 68 |
Implied Table |
Table |
* |
* |
implied:Table |
| 69 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 70 |
Cash used in operating activities: |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract |
| 71 |
Loss before taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 72 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 73 |
Finance expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 74 |
Share-based payment charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForSharebasedPayments |
| 75 |
Increase in prepayments and other receivables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables |
| 76 |
Increase in trade and other payables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables |
| 77 |
Depreciation of property, plant and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDepreciationExpense |
| 78 |
Loss on disposal of property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment |
| 79 |
Loss on disposal of property plant and equipment |
Concept (Monetary) |
For Period |
Debit |
vrna:AdjustmentsForGainLossOnDisposalsIntangibleAssets |
| 80 |
Amortization of intangible assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForAmortisationExpense |
| 81 |
Cash used in operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperations |
| 82 |
Cash inflow from taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities |
| 83 |
Net cash used in operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperatingActivities |
| 84 |
Cash flow from investing activities: |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract |
| 85 |
Interest received |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestReceivedClassifiedAsInvestingActivities |
| 86 |
Purchase of plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 87 |
Payment for patents and computer software |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities |
| 88 |
Purchase of short term investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments |
| 89 |
Maturity of short term investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets |
| 90 |
Net cash generated from / (used in) investing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 91 |
Cash flow from financing activities: |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract |
| 92 |
Gross proceeds from issue of shares and warrants |
Concept (Monetary) |
For Period |
Debit |
vrna:ProceedsFromIssuingSharesAndWarrants |
| 93 |
Gross proceeds from the April 2017 Global Offering |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 94 |
Transaction costs on issue of shares and warrants |
Concept (Monetary) |
For Period |
Credit |
vrna:PaymentsForShareandWarrantIssueCosts |
| 95 |
Transaction costs on April 2017 Global Offering |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PaymentsForShareIssueCosts |
| 96 |
Net cash generated from financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 97 |
Net (decrease) / increase in cash and cash equivalents |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges |
| 98 |
Cash and cash equivalents at the beginning of the year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 99 |
Effect of exchange rates on cash and cash equivalents |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| 100 |
Cash and cash equivalents at the end of the year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 101 |
1004000 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY |
Network |
* |
* |
http://www.veronapharma.com/role/ConsolidatedStatementOfChangesInEquity |
| 102 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 103 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 104 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 105 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 106 |
Share Premium |
Member |
|
|
ifrs-full:SharePremiumMember |
| 107 |
Share-based Payment Reserve |
Member |
|
|
ifrs-full:ReserveOfSharebasedPaymentsMember |
| 108 |
Total Accumulated Losses |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 109 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 110 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 111 |
Loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 112 |
Exchange differences on translating foreign operations |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation |
| 113 |
Total comprehensive loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent |
| 114 |
New share capital issued |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 115 |
Transaction costs on share capital issued |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 116 |
Share options exercised during the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions |
| 117 |
Share-based payments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions |
| 118 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 119 |
2101100 - Disclosure - General information |
Network |
* |
* |
http://www.veronapharma.com/role/GeneralInformation |
| 120 |
Implied Table |
Table |
* |
* |
implied:Table |
| 121 |
Disclosure of notes and other explanatory information [Abstract] |
Abstract |
|
|
vrna:DisclosureofnotesandotherexplanatoryinformationAbstract |
| 122 |
General information |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory |
| 123 |
2104100 - Disclosure - Accounting policies |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPolicies |
| 124 |
Implied Table |
Table |
* |
* |
implied:Table |
| 125 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 126 |
Accounting policies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 127 |
2107100 - Disclosure - Financial Instruments |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstruments |
| 128 |
Implied Table |
Table |
* |
* |
implied:Table |
| 129 |
Disclosure of detailed information about financial instruments [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 130 |
Financial Instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsExplanatory |
| 131 |
2110100 - Disclosure - Critical accounting estimates and judgments |
Network |
* |
* |
http://www.veronapharma.com/role/CriticalAccountingEstimatesAndJudgments |
| 132 |
Implied Table |
Table |
* |
* |
implied:Table |
| 133 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 134 |
Critical accounting estimates and judgments |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfCriticalAccountingEstimatesTextBlock |
| 135 |
2113100 - Disclosure - Earnings per share |
Network |
* |
* |
http://www.veronapharma.com/role/EarningsPerShare |
| 136 |
Implied Table |
Table |
* |
* |
implied:Table |
| 137 |
Disclosure of earnings per share [Abstract] |
Abstract |
|
|
vrna:DisclosureofearningspershareAbstract |
| 138 |
Earnings per share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:EarningsPerShareExplanatory |
| 139 |
2116100 - Disclosure - Segmental reporting |
Network |
* |
* |
http://www.veronapharma.com/role/SegmentalReporting |
| 140 |
Implied Table |
Table |
* |
* |
implied:Table |
| 141 |
Disclosure of entity's operating segments [Abstract] |
Abstract |
|
|
vrna:DisclosureofentitysoperatingsegmentsAbstract |
| 142 |
Segmental reporting |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory |
| 143 |
2119100 - Disclosure - Operating loss |
Network |
* |
* |
http://www.veronapharma.com/role/OperatingLoss |
| 144 |
Implied Table |
Table |
* |
* |
implied:Table |
| 145 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 146 |
Operating loss |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory |
| 147 |
2122100 - Disclosure - Directors' emoluments and staff costs |
Network |
* |
* |
http://www.veronapharma.com/role/DirectorsEmolumentsAndStaffCosts |
| 148 |
Implied Table |
Table |
* |
* |
implied:Table |
| 149 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 150 |
Directors' emoluments and staff costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEmployeeBenefitsExplanatory |
| 151 |
2125100 - Disclosure - Finance income and expense |
Network |
* |
* |
http://www.veronapharma.com/role/FinanceIncomeAndExpense |
| 152 |
Implied Table |
Table |
* |
* |
implied:Table |
| 153 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 154 |
Finance income and expense |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory |
| 155 |
2128100 - Disclosure - Taxation |
Network |
* |
* |
http://www.veronapharma.com/role/Taxation |
| 156 |
Implied Table |
Table |
* |
* |
implied:Table |
| 157 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
vrna:DisclosureofincometaxAbstract |
| 158 |
Taxation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIncomeTaxExplanatory |
| 159 |
2131100 - Disclosure - Goodwill |
Network |
* |
* |
http://www.veronapharma.com/role/Goodwill |
| 160 |
Implied Table |
Table |
* |
* |
implied:Table |
| 161 |
Disclosure of detailed information about intangible assets [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 162 |
Goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGoodwillExplanatory |
| 163 |
2134100 - Disclosure - Intangible assets |
Network |
* |
* |
http://www.veronapharma.com/role/IntangibleAssets |
| 164 |
Implied Table |
Table |
* |
* |
implied:Table |
| 165 |
Disclosure of detailed information about intangible assets [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 166 |
Intangible assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIntangibleAssetsExplanatory |
| 167 |
2137100 - Disclosure - Property, plant and equipment |
Network |
* |
* |
http://www.veronapharma.com/role/PropertyPlantAndEquipment |
| 168 |
Implied Table |
Table |
* |
* |
implied:Table |
| 169 |
Disclosure of detailed information about property, plant and equipment [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 170 |
Property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory |
| 171 |
2140100 - Disclosure - Prepayments and other receivables |
Network |
* |
* |
http://www.veronapharma.com/role/PrepaymentsAndOtherReceivables |
| 172 |
Implied Table |
Table |
* |
* |
implied:Table |
| 173 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 174 |
Prepayments and other receivables |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory |
| 175 |
2149100 - Disclosure - Share Capital |
Network |
* |
* |
http://www.veronapharma.com/role/ShareCapital |
| 176 |
Implied Table |
Table |
* |
* |
implied:Table |
| 177 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 178 |
Share Capital |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory |
| 179 |
2152100 - Disclosure - Share-based payments charge |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsCharge |
| 180 |
Implied Table |
Table |
* |
* |
implied:Table |
| 181 |
Disclosure of share-based payment arrangements [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharebasedpaymentarrangementsAbstract |
| 182 |
Share-based payments charge |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory |
| 183 |
2155100 - Disclosure - Trade and other payables |
Network |
* |
* |
http://www.veronapharma.com/role/TradeAndOtherPayables |
| 184 |
Implied Table |
Table |
* |
* |
implied:Table |
| 185 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 186 |
Trade and other payables |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory |
| 187 |
2158100 - Disclosure - Assumed contingent obligation related to the business combination |
Network |
* |
* |
http://www.veronapharma.com/role/AssumedContingentObligationRelatedToBusinessCombination |
| 188 |
Implied Table |
Table |
* |
* |
implied:Table |
| 189 |
Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] |
Abstract |
|
|
vrna:DisclosureofotherprovisionscontingentliabilitiesandcontingentassetsAbstract |
| 190 |
Assumed contingent obligation related to the business combination |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfContingentLiabilitiesExplanatory |
| 191 |
2161100 - Disclosure - Warrants |
Network |
* |
* |
http://www.veronapharma.com/role/Warrants |
| 192 |
Implied Table |
Table |
* |
* |
implied:Table |
| 193 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 194 |
Warrants |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfWarrantsExplanatoryTextBlock |
| 195 |
2164100 - Disclosure - Financial commitments |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialCommitments |
| 196 |
Implied Table |
Table |
* |
* |
implied:Table |
| 197 |
Disclosure of leases [Abstract] |
Abstract |
|
|
vrna:DisclosureofleasesAbstract |
| 198 |
Financial commitments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory |
| 199 |
2167100 - Disclosure - Related parties transactions and other shareholder matters |
Network |
* |
* |
http://www.veronapharma.com/role/RelatedPartiesTransactionsAndOtherShareholderMatters |
| 200 |
Implied Table |
Table |
* |
* |
implied:Table |
| 201 |
Disclosure of related party [Abstract] |
Abstract |
|
|
vrna:DisclosureofrelatedpartyAbstract |
| 202 |
Related parties transactions and other shareholder matters |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRelatedPartyExplanatory |
| 203 |
2204201 - Disclosure - Accounting policies (Policies) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesPolicies |
| 204 |
Implied Table |
Table |
* |
* |
implied:Table |
| 205 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 206 |
Going concern |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock |
| 207 |
Business combination |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory |
| 208 |
Basis of consolidation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory |
| 209 |
Foreign currency translation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory |
| 210 |
Cash and cash equivalents |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents |
| 211 |
Deferred taxation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory |
| 212 |
Research and development costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory |
| 213 |
Property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory |
| 214 |
Intangible assets and goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory |
| 215 |
Impairment of intangible assets, goodwill and non-financial asset |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory |
| 216 |
Employee Benefits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory |
| 217 |
Share-based payments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory |
| 218 |
Provisions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory |
| 219 |
Assumed contingent obligation related to the business combinations |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory |
| 220 |
Government and other grants |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants |
| 221 |
Financial instruments — initial recognition and subsequent measurement |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory |
| 222 |
Warrants |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory |
| 223 |
Short Term Investments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory |
| 224 |
Transaction costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory |
| 225 |
Investments in subsidiaries |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfAccountingPolicyForInvestmentInSubsidiaryPolicyTextBlock |
| 226 |
New standards, amendments and interpretations adopted by the Group |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsPolicyTextBlock |
| 227 |
New standards, amendments and interpretations issued but not effective for the financial year beginning January 1, 2016 and not early adopted |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfAccountingPolicyForNewstandardsAmendmentsAndInterpretationsIssuedButNotEffectivePolicyTextBlock |
| 228 |
2304302 - Disclosure - Accounting policies (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesTables |
| 229 |
Implied Table |
Table |
* |
* |
implied:Table |
| 230 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 231 |
Description of property, plant and equipment useful life |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock |
| 232 |
2307301 - Disclosure - Financial Instruments (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsTables |
| 233 |
Implied Table |
Table |
* |
* |
implied:Table |
| 234 |
Disclosure of detailed information about financial instruments [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 235 |
Summary quantitative data about entity's exposure to risk |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:SummaryQuantitativeDataAboutEntitysExposureToRisk |
| 236 |
Disclosure of effect of changes in foreign exchange rates |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk |
| 237 |
Disclosure of cash and cash equivalents and short term investments |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsPlacementExplanatoryTableTextBlock |
| 238 |
Disclosure of financial instruments by type of interest rate |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory |
| 239 |
Disclosure of maturity analysis of undiscounted cash outflows to repurchase derecognised financial assets or amounts payable to transferee in respect of transferred assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfMaturityAnalysisOfUndiscountedCashOutflowsToRepurchaseDerecognisedFinancialAssetsExplanatory |
| 240 |
Disclosure of fair value measurement of assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory |
| 241 |
Disclosure of fair value measurement of liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory |
| 242 |
Disclosure of significant unobservable inputs used in fair value measurement of liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory |
| 243 |
2319301 - Disclosure - Operating loss (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/OperatingLossTables |
| 244 |
Implied Table |
Table |
* |
* |
implied:Table |
| 245 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 246 |
Description of operating loss |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DescriptionOfOperatingLossTableTextBlock |
| 247 |
2322301 - Disclosure - Directors' emoluments and staff costs (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/DirectorsEmolumentsAndStaffCostsTables |
| 248 |
Implied Table |
Table |
* |
* |
implied:Table |
| 249 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 250 |
Disclosure of information about employees |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory |
| 251 |
2325301 - Disclosure - Finance income and expense (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/FinanceIncomeAndExpenseTables |
| 252 |
Implied Table |
Table |
* |
* |
implied:Table |
| 253 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 254 |
Disclosure of finance income |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceIncomeExplanatory |
| 255 |
Disclosure of finance expense |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceCostExplanatory |
| 256 |
2328301 - Disclosure - Taxation (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/TaxationTables |
| 257 |
Implied Table |
Table |
* |
* |
implied:Table |
| 258 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
vrna:DisclosureofincometaxAbstract |
| 259 |
Disclosure of major tax components |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfMajorComponentsOfTaxExpenseIncomeTableTextBlock |
| 260 |
Disclosure of temporary difference, unused tax losses and unused tax credits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory |
| 261 |
2331301 - Disclosure - Goodwill (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/GoodwillTables |
| 262 |
Implied Table |
Table |
* |
* |
implied:Table |
| 263 |
Disclosure of detailed information about intangible assets [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 264 |
Disclosure of reconciliation of changes in goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory |
| 265 |
2334301 - Disclosure - Intangible assets (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/IntangibleAssetsTables |
| 266 |
Implied Table |
Table |
* |
* |
implied:Table |
| 267 |
Disclosure of detailed information about intangible assets [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 268 |
Disclosure of reconciliation of changes in intangible assets and goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory |
| 269 |
2337301 - Disclosure - Property, plant and equipment (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/PropertyPlantAndEquipmentTables |
| 270 |
Implied Table |
Table |
* |
* |
implied:Table |
| 271 |
Disclosure of detailed information about property, plant and equipment [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 272 |
Disclosure of detailed information about property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 273 |
2340301 - Disclosure - Prepayments and other receivables (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/PrepaymentsAndOtherReceivablesTables |
| 274 |
Implied Table |
Table |
* |
* |
implied:Table |
| 275 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 276 |
Description of prepayments and other receivables |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfPrepaymentsAndOtherReceivablesTableTextBlock |
| 277 |
2349301 - Disclosure - Share Capital (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareCapitalTables |
| 278 |
Implied Table |
Table |
* |
* |
implied:Table |
| 279 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 280 |
Movements in the Company's share capital |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory |
| 281 |
2352301 - Disclosure - Share-based payments charge (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeTables |
| 282 |
Implied Table |
Table |
* |
* |
implied:Table |
| 283 |
Disclosure of share-based payment arrangements [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharebasedpaymentarrangementsAbstract |
| 284 |
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory |
| 285 |
Disclosure of number and weighted average exercise prices of share options |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory |
| 286 |
Disclosure of number and weighted average exercise prices of other equity instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory |
| 287 |
2355301 - Disclosure - Trade and other payables (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/TradeAndOtherPayablesTables |
| 288 |
Implied Table |
Table |
* |
* |
implied:Table |
| 289 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 290 |
Disclosure of trade and other payables |
Concept (Text Block (HTML)) |
For Period |
|
vrna:DisclosureOfTradeAndOtherPayables |
| 291 |
2358301 - Disclosure - Assumed contingent obligation related to the business combination (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/AssumedContingentObligationRelatedToBusinessCombinationTables |
| 292 |
Implied Table |
Table |
* |
* |
implied:Table |
| 293 |
Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] |
Abstract |
|
|
vrna:DisclosureofotherprovisionscontingentliabilitiesandcontingentassetsAbstract |
| 294 |
Disclosure of contingent liabilities in business combination |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfContingentLiabilitiesInBusinessCombinationExplanatory |
| 295 |
2361301 - Disclosure - Warrants (Tables) |
Network |
* |
* |
http://www.veronapharma.com/role/WarrantsTables |
| 296 |
Implied Table |
Table |
* |
* |
implied:Table |
| 297 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 298 |
Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory |
| 299 |
2401401 - Disclosure - General information (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/GeneralInformationDetails |
| 300 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 301 |
Sale Of Stock [Axis] |
Axis |
|
|
vrna:SaleOfStockAxis |
| 302 |
Sale Of Stock [Domain] |
Member |
|
|
vrna:SaleOfStockDomain |
| 303 |
Global Offering |
Member |
|
|
vrna:GlobalOfferingMember |
| 304 |
IPO |
Member |
|
|
vrna:IPO1Member |
| 305 |
Private Placement |
Member |
|
|
vrna:PrivatePlacement1Member |
| 306 |
Shareholder Private Placement |
Member |
|
|
vrna:ShareholderPrivatePlacementMember |
| 307 |
Over-Allotment Option |
Member |
|
|
vrna:OverAllotmentOption1Member |
| 308 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 309 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 310 |
Global Offering |
Member |
|
|
vrna:GlobalOfferingMember |
| 311 |
ADS |
Member |
|
|
vrna:AmericanDepositarySharesMember |
| 312 |
Ordinary shares |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 313 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 314 |
Number of subsidiaries |
Concept (Integer) |
For Period |
|
vrna:NumberOfSubsidiaries |
| 315 |
Consolidation of shares |
Concept (Pure) |
For Period |
|
vrna:StockholdersEquityNoteStockSplitConversionRatio2 |
| 316 |
Number of units issued (in shares) |
Concept (Shares) |
As Of |
|
vrna:NumberOfSharesIssuedInOffering |
| 317 |
Shares issued price (in dollars or pounds per share) |
Concept (Share) |
As Of |
|
vrna:SaleofStockPricePerShare1 |
| 318 |
Gross proceeds from the April 2017 Global Offering |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 319 |
2404403 - Disclosure - Accounting policies - Going concern (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesGoingConcernDetails |
| 320 |
Implied Table |
Table |
* |
* |
implied:Table |
| 321 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 322 |
Loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 323 |
Net assets |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 324 |
Cash and cash equivalents and short term investments |
Concept (Monetary) |
As Of |
Debit |
vrna:CashAndCashEquivalentsIncludingShortTermDeposits |
| 325 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 326 |
Gross proceeds from the April 2017 Global Offering |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 327 |
Gross proceeds from issue of shares and warrants |
Concept (Monetary) |
For Period |
Debit |
vrna:ProceedsFromIssuingSharesAndWarrants |
| 328 |
2404404 - Disclosure - Accounting policies - Description of property, plant and equipment useful life (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesDescriptionOfPropertyPlantAndEquipmentUsefulLifeDetails |
| 329 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 330 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 331 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 332 |
Computer hardware |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 333 |
Office equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 334 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 335 |
Property, plant and equipment life |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod |
| 336 |
2404405 - Disclosure - Accounting policies - Intangible assets and goodwill (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesIntangibleAssetsAndGoodwillDetails |
| 337 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 338 |
Classes of intangible assets and goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis |
| 339 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 340 |
Patents |
Member |
|
|
ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember |
| 341 |
Computer software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 342 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 343 |
Estimated useful lives |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:FiniteLivedIntangibleAssetUsefulLife1 |
| 344 |
2404406 - Disclosure - Accounting policies - Assumed contingent obligation related to the business combinations (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesAssumedContingentObligationRelatedToBusinessCombinationsDetails |
| 345 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 346 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 347 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 348 |
Rhinopharma Limited |
Member |
|
|
vrna:RhinopharmaLimitedMember |
| 349 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 350 |
Consideration payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityInterestsOfAcquirer |
| 351 |
Effective interest rate |
Concept (Percent) |
For Period |
|
vrna:DiscountRateAppliedToContingentObligation |
| 352 |
2404407 - Disclosure - Accounting policies - New standards, amendments and interpretations issued but not effective (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AccountingPoliciesNewStandardsAmendmentsAndInterpretationsIssuedButNotEffectiveDetails |
| 353 |
Implied Table |
Table |
* |
* |
implied:Table |
| 354 |
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] |
Abstract |
|
|
vrna:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract |
| 355 |
Lease liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LeaseLiabilities |
| 356 |
Lease assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:RightofuseAssets |
| 357 |
Number of leases |
Concept (Integer) |
For Period |
|
vrna:NumberOfOperatingLeases |
| 358 |
2407402 - Disclosure - Financial Instruments - Summary quantitative data about entity's exposure to risk (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsSummaryQuantitativeDataAboutEntitysExposureToRiskDetails |
| 359 |
Disclosure of credit risk exposure [table] |
Table |
* |
* |
ifrs-full:DisclosureOfCreditRiskExposureTable |
| 360 |
Currency [Axis] |
Axis |
|
|
srt:CurrencyAxis |
| 361 |
All Currencies [Domain] |
Member |
|
|
currency:AllCurrenciesDomain |
| 362 |
USD |
Member |
|
|
currency:USD |
| 363 |
EUR |
Member |
|
|
currency:EUR |
| 364 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 365 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 366 |
Currency risk |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 367 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 368 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 369 |
Cash and cash equivalents |
Member |
|
|
vrna:CashAndCashEquivalents1Member |
| 370 |
Short Term Investments |
Member |
|
|
vrna:ShortTermInvestments1Member |
| 371 |
Trade and other payables |
Member |
|
|
vrna:AccountsPayableAndAccruedLiabilities1Member |
| 372 |
Disclosure of credit risk exposure [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfCreditRiskExposureLineItems |
| 373 |
Cash deposits |
Concept (Monetary) |
As Of |
|
ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic |
| 374 |
2407403 - Disclosure - Financial Instruments - Disclosure of effect of changes in foreign exchange rates [text block] (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfEffectOfChangesInForeignExchangeRatesTextBlockDetails |
| 375 |
Disclosure of credit risk exposure [table] |
Table |
* |
* |
ifrs-full:DisclosureOfCreditRiskExposureTable |
| 376 |
Currency [Axis] |
Axis |
|
|
srt:CurrencyAxis |
| 377 |
All Currencies [Domain] |
Member |
|
|
currency:AllCurrenciesDomain |
| 378 |
EUR |
Member |
|
|
currency:EUR |
| 379 |
USD |
Member |
|
|
currency:USD |
| 380 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 381 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 382 |
Strengthening |
Member |
|
|
vrna:CurrencyRiskStrengtheningMember |
| 383 |
Weakening |
Member |
|
|
vrna:CurrencyRiskWeakeningMember |
| 384 |
Disclosure of credit risk exposure [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfCreditRiskExposureLineItems |
| 385 |
Profit or loss and equity |
Concept (Monetary) |
For Period |
Credit |
vrna:SensitivityAnalysisForFivePercentMovementInForeignCurrencyAffectProfitLossAndEquityNetOfTax |
| 386 |
2407404 - Disclosure - Financial Instruments - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsNarrativeDetails |
| 387 |
Disclosure of fair value measurement of assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsTable |
| 388 |
Classes of liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfLiabilitiesAxis |
| 389 |
Liabilities [member] |
Member |
|
|
ifrs-full:LiabilitiesMember |
| 390 |
Derivative financial instrument |
Member |
|
|
ifrs-full:DerivativesMember |
| 391 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 392 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 393 |
Level 3 |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 394 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 395 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 396 |
Bottom of range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 397 |
Top of range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 398 |
Disclosure of fair value measurement of assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsLineItems |
| 399 |
Trade payable term |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:TradePayablesForeignCurrencyDenominatedTerm |
| 400 |
Cash deposits |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 401 |
Short-term deposits, not classified as cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents |
| 402 |
Rates of interest |
Concept (Percent) |
For Period |
|
vrna:InterestRateReceivedOnCashDeposits |
| 403 |
Increase in interest rates |
Concept (Percent) |
For Period |
|
vrna:IncreaseDecreaseInInterestRateReceivedOnCashDeposits |
| 404 |
Gains (losses) recognised in profit or loss, fair value measurement, liabilities |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities |
| 405 |
2407405 - Disclosure - Financial Instruments - Disclosure Of Detailed Information About Cash And Cash Equivalents Placement Explanatory (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfDetailedInformationAboutCashAndCashEquivalentsPlacementExplanatoryDetails |
| 406 |
Disclosure of financial assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialAssetsTable |
| 407 |
Bank Name [Axis] |
Axis |
|
|
vrna:BankNameAxis |
| 408 |
Bank Name [Domain] |
Member |
|
|
vrna:BankNameDomain |
| 409 |
Royal Bank of Scotland |
Member |
|
|
vrna:RoyalBankOfScotlandMember |
| 410 |
Lloyds Bank |
Member |
|
|
vrna:LloydsBankMember |
| 411 |
Standard Chartered |
Member |
|
|
vrna:StandardCharteredMember |
| 412 |
Citibank [Member] [Domain] |
Member |
|
|
vrna:CitibankDomain |
| 413 |
Barclays [Member] [Domain] [Domain] |
Member |
|
|
vrna:BarclaysDomain |
| 414 |
Wells Fargo |
Member |
|
|
vrna:WellsFargoMember |
| 415 |
Disclosure of financial assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialAssetsLineItems |
| 416 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 417 |
Short term investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents |
| 418 |
2407406 - Disclosure - Financial Instruments - Disclosure of financial instruments by type of interest rate (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfFinancialInstrumentsByTypeOfInterestRateDetails |
| 419 |
Disclosure of financial instruments by type of interest rate [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable |
| 420 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 421 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 422 |
Cash deposits |
Member |
|
|
vrna:CashDepositsMember |
| 423 |
Short Term Investments |
Member |
|
|
vrna:ShortTermInvestments1Member |
| 424 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 425 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 426 |
Interest rate risk |
Member |
|
|
ifrs-full:InterestRateRiskMember |
| 427 |
Types of interest rates [axis] |
Axis |
|
|
ifrs-full:TypesOfInterestRatesAxis |
| 428 |
Interest rate types [member] |
Member |
|
|
ifrs-full:InterestRateTypesMember |
| 429 |
Floating interest rate |
Member |
|
|
ifrs-full:FloatingInterestRateMember |
| 430 |
Fixed Interest rate |
Member |
|
|
ifrs-full:FixedInterestRateMember |
| 431 |
Disclosure of financial instruments by type of interest rate [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems |
| 432 |
Short-term deposits, not classified as cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents |
| 433 |
Cash deposits |
Concept (Monetary) |
As Of |
|
ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic |
| 434 |
2407407 - Disclosure - Financial Instruments - Disclosure of maturity analysis of undiscounted cash outflows to repurchase derecognised financial assets or amounts payable to transferee in respect of transferred assets (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfMaturityAnalysisOfUndiscountedCashOutflowsToRepurchaseDerecognisedFinancialAssetsOrAmountsPayableToTransfereeInRespectOfTransferredAssetsDetails |
| 435 |
Disclosure of financial liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialLiabilitiesTable |
| 436 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 437 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 438 |
Liquidity risk |
Member |
|
|
ifrs-full:LiquidityRiskMember |
| 439 |
Classes of liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfLiabilitiesAxis |
| 440 |
Liabilities [member] |
Member |
|
|
ifrs-full:LiabilitiesMember |
| 441 |
Trade payables |
Member |
|
|
vrna:TradePayablesMember |
| 442 |
Other payables |
Member |
|
|
vrna:OtherPayablesMember |
| 443 |
Accruals |
Member |
|
|
vrna:AccrualsMember |
| 444 |
Contingent obligation |
Member |
|
|
vrna:ContingentObligationMember |
| 445 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 446 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 447 |
LESS THAN 1 YEAR |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 448 |
BETWEEN 1 AND 2 YEARS |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 449 |
BETWEEN 2 AND 5 YEARS |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember |
| 450 |
OVER 5 YEARS |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 451 |
Disclosure of financial liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialLiabilitiesLineItems |
| 452 |
Trade and other payables, undiscounted cash flows |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows |
| 453 |
Milestone payment |
Concept (Monetary) |
As Of |
|
ifrs-full:EstimatedFinancialEffectContingentLiabilitiesInBusinessCombination |
| 454 |
2407408 - Disclosure - Financial Instruments - Disclosure of fair value measurement of assets and liabilities (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesDetails |
| 455 |
Disclosure of fair value measurement of assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsTable |
| 456 |
Classes of liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfLiabilitiesAxis |
| 457 |
Liabilities [member] |
Member |
|
|
ifrs-full:LiabilitiesMember |
| 458 |
Derivative financial instrument |
Member |
|
|
ifrs-full:DerivativesMember |
| 459 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 460 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 461 |
Level 3 |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 462 |
Disclosure of fair value measurement of assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsLineItems |
| 463 |
Financial assets |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 464 |
2407409 - Disclosure - Financial Instruments - Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsDisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesDetails |
| 465 |
Disclosure of fair value of plan assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFairValueOfPlanAssetsTable |
| 466 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 467 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 468 |
Level 3 |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 469 |
Classes of liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfLiabilitiesAxis |
| 470 |
Liabilities [member] |
Member |
|
|
ifrs-full:LiabilitiesMember |
| 471 |
Derivative financial instrument |
Member |
|
|
ifrs-full:DerivativesMember |
| 472 |
Disclosure of fair value of plan assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFairValueOfPlanAssetsLineItems |
| 473 |
Reconciliation of changes in fair value measurement, liabilities [abstract] |
Abstract |
|
|
ifrs-full:ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract |
| 474 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 475 |
Initial recognition of derivative financial instrument |
Concept (Monetary) |
For Period |
Credit |
vrna:WarrantsandRightsIssuedDuringPeriod |
| 476 |
Fair value adjustments recognized in profit and loss |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities |
| 477 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 478 |
2407410 - Disclosure - Financial Instruments - Change in liabilities arising from financing activities (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialInstrumentsChangeInLiabilitiesArisingFromFinancingActivitiesDetails |
| 479 |
Disclosure of fair value measurement of liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesTable |
| 480 |
Classes of liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfLiabilitiesAxis |
| 481 |
Liabilities [member] |
Member |
|
|
ifrs-full:LiabilitiesMember |
| 482 |
Derivative financial instrument |
Member |
|
|
ifrs-full:DerivativesMember |
| 483 |
Disclosure of fair value measurement of liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesLineItems |
| 484 |
Changes in fair value measurement, liabilities [abstract] |
Abstract |
|
|
ifrs-full:ChangesInFairValueMeasurementLiabilitiesAbstract |
| 485 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 486 |
Fair value adjustments - non cash |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities |
| 487 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 488 |
2410401 - Disclosure - Critical accounting estimates and judgments (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/CriticalAccountingEstimatesAndJudgmentsDetails |
| 489 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 490 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 491 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 492 |
Clinical Research Organization |
Member |
|
|
vrna:ClinicalResearchOrganizationMember |
| 493 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 494 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 495 |
Warrants |
Member |
|
|
vrna:Warrant1Member |
| 496 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 497 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 498 |
Rhinopharma Limited |
Member |
|
|
vrna:RhinopharmaLimitedMember |
| 499 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 500 |
Assumed contingent obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 501 |
Reported change to the value of the liability |
Concept (Monetary) |
For Period |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationImpactOfReasonablyPossibleReductionInAssumedDiscountRate |
| 502 |
Discount percent |
Concept (Percent) |
For Period |
|
vrna:DiscountRateAppliedToContingentObligation |
| 503 |
Number of units issued (in shares) |
Concept (Shares) |
As Of |
|
vrna:NumberOfSharesIssuedInOffering |
| 504 |
Placing price (in pounds per unit) |
Concept (Share) |
As Of |
|
vrna:SaleofStockPricePerShare1 |
| 505 |
Number of ordinary shares (in shares) |
Concept (Integer) |
As Of |
|
vrna:NumberOfOrdinarySharesComprisingUnit |
| 506 |
Number warrants (in warrants) |
Concept (Integer) |
As Of |
|
vrna:NumberOfWarrantsComprisingUnit |
| 507 |
Number of shares subscribed from warrant maximum (in shares) |
Concept (Shares) |
As Of |
|
vrna:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 508 |
Research and development expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 509 |
Accruals |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Accruals |
| 510 |
Prepayments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Prepayments |
| 511 |
2413401 - Disclosure - Earnings per share (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/EarningsPerShareDetails |
| 512 |
Implied Table |
Table |
* |
* |
implied:Table |
| 513 |
Disclosure of earnings per share [Abstract] |
Abstract |
|
|
vrna:DisclosureofearningspershareAbstract |
| 514 |
Basic loss per share (pounds per share) |
Concept (Share) |
For Period |
|
ifrs-full:BasicEarningsLossPerShare |
| 515 |
Weighted average number of ordinary shares (in shares) |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 516 |
2416401 - Disclosure - Segmental reporting (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/SegmentalReportingDetails |
| 517 |
Implied Table |
Table |
* |
* |
implied:Table |
| 518 |
Disclosure of entity's operating segments [Abstract] |
Abstract |
|
|
vrna:DisclosureofentitysoperatingsegmentsAbstract |
| 519 |
Number of operating and reportable segments |
Concept (Integer) |
For Period |
|
vrna:NumberofReportableSegments |
| 520 |
2419402 - Disclosure - Operating loss - Description Of Operating Loss (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/OperatingLossDescriptionOfOperatingLossDetails |
| 521 |
Document Information [Table] |
Table |
* |
* |
dei:DocumentInformationTable |
| 522 |
Income Statement Location [Axis] |
Axis |
|
|
vrna:IncomeStatementLocation1Axis |
| 523 |
Income Statement Location [Domain] |
Member |
|
|
vrna:IncomeStatementLocation1Domain |
| 524 |
Research and development costs |
Member |
|
|
vrna:ResearchAndDevelopmentExpense1Member |
| 525 |
General and administrative costs |
Member |
|
|
vrna:SellingGeneralAndAdministrativeExpenseMember |
| 526 |
Classes of intangible assets and goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis |
| 527 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 528 |
Patents |
Member |
|
|
ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember |
| 529 |
Computer software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 530 |
Document Information [Line Items] |
LineItems |
|
|
dei:DocumentInformationLineItems |
| 531 |
Research and development costs: |
Abstract |
|
|
vrna:ResearchAndDevelopmentCostsAbstract |
| 532 |
Employee benefits (note 8) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 533 |
Amortization |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AmortisationExpense |
| 534 |
Legal, professional consulting and listing fees |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProfessionalFeesExpense |
| 535 |
Other research and development expenses |
Concept (Monetary) |
For Period |
Debit |
vrna:OtherResearchAndDevelopmentExpense1 |
| 536 |
Total research and development costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 537 |
General and administrative costs: |
Abstract |
|
|
ifrs-full:SellingGeneralAndAdministrativeExpenseAbstract |
| 538 |
Employee benefits (note 8) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 539 |
Legal, professional consulting and listing fees |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProfessionalFeesExpense |
| 540 |
Amortization |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AmortisationExpense |
| 541 |
Loss on disposal of property, plant and equipment (note 13) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment |
| 542 |
Depreciation of property, plant and equipment (note 13) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DepreciationExpense |
| 543 |
Operating lease charge — land and buildings |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:MinimumOperatingLeasePayments |
| 544 |
(Gain) / Loss on variations in foreign exchange rate |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 545 |
Other general and administrative expenses |
Concept (Monetary) |
For Period |
Debit |
vrna:OtherSellingGeneralandAdministrativeExpense |
| 546 |
Total general and administrative costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GeneralAndAdministrativeExpense |
| 547 |
Operating loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 548 |
2422402 - Disclosure - Directors' emoluments and staff costs (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/DirectorsEmolumentsAndStaffCostsDetails |
| 549 |
Disclosure of transactions between related parties [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable |
| 550 |
Employee Group [Axis] |
Axis |
|
|
vrna:EmployeeGroupAxis |
| 551 |
Employee Group [Domain] |
Member |
|
|
vrna:EmployeeGroupDomain |
| 552 |
Research and Development |
Member |
|
|
vrna:ResearchAndDevelopmentGroupMember |
| 553 |
General and Administrative |
Member |
|
|
vrna:GeneralandAdministrativeGroupMember |
| 554 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 555 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 556 |
Directors |
Member |
|
|
ifrs-full:KeyManagementPersonnelOfEntityOrParentMember |
| 557 |
Executive Officers |
Member |
|
|
vrna:ExecutiveOfficersMember |
| 558 |
Other Staff |
Member |
|
|
vrna:PersonnelExcludingDirectorsOfEntityOrParentMember |
| 559 |
Disclosure of transactions between related parties [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems |
| 560 |
The average number of employees (excluding directors) of the Company during the year: |
Concept (Decimal) |
For Period |
|
ifrs-full:AverageNumberOfEmployees |
| 561 |
Aggregate emoluments of directors: |
Abstract |
|
|
vrna:AggregateEmolumentsOfDirectorsAbstract |
| 562 |
Salaries and other short-term employee benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShorttermEmployeeBenefitsExpense |
| 563 |
Social security costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SocialSecurityContributions |
| 564 |
Incremental payment for additional services |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherEmployeeExpense |
| 565 |
Other pension costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherLongtermBenefits |
| 566 |
Total directors' emoluments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 567 |
Share-based payment charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 568 |
Directors' emoluments including share-based payment charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DirectorsRemunerationExpense |
| 569 |
Aggregate other staff costs: |
Abstract |
|
|
vrna:AggregateOtherStaffCostsAbstract |
| 570 |
Wages and salaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:WagesAndSalaries |
| 571 |
Social security costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SocialSecurityContributions |
| 572 |
Incremental payment for additional services |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherEmployeeExpense |
| 573 |
Share-based payment charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 574 |
Other pension costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherLongtermBenefits |
| 575 |
Total other staff costs |
Concept (Monetary) |
For Period |
Debit |
vrna:StaffExcludingDirectorsRemunerationExpense |
| 576 |
Post-employment benefit expense, defined contribution plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans |
| 577 |
Prepaid or accrued contributions |
Concept (Monetary) |
As Of |
Debit |
vrna:PrepaidOrAccruedContributions |
| 578 |
2425402 - Disclosure - Finance income and expense (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinanceIncomeAndExpenseDetails |
| 579 |
Implied Table |
Table |
* |
* |
implied:Table |
| 580 |
Analysis of income and expense [abstract] |
Abstract |
|
|
ifrs-full:AnalysisOfIncomeAndExpenseAbstract |
| 581 |
Finance income: |
Abstract |
|
|
ifrs-full:RevenueAbstract |
| 582 |
Interest received on cash balances |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks |
| 583 |
Foreign exchange gain on translating foreign currency denominated balances |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:NetForeignExchangeGain |
| 584 |
Fair value adjustment on derivative financial instruments (note 17) |
Concept (Monetary) |
For Period |
Credit |
vrna:FairValueAdjustmentofWarrantsIncome |
| 585 |
Other Income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherFinanceIncome |
| 586 |
Total finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 587 |
Finance expense: |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 588 |
Fair value adjustment on derivative financial instruments (note 17) |
Concept (Monetary) |
For Period |
Debit |
vrna:FairValueAdjustmentofWarrantsExpense |
| 589 |
Transaction costs allocated to the issue of warrants (note 17) |
Concept (Monetary) |
For Period |
Debit |
vrna:WarrantIssueRelatedCost |
| 590 |
Foreign exchange loss on translating foreign currency denominated balances |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:NetForeignExchangeLoss |
| 591 |
Remeasurement of assumed contingent arrangement |
Concept (Monetary) |
For Period |
Debit |
vrna:GainsLossesOnFairValueAdjustmentContingentLiabilities |
| 592 |
Unwinding of discount factor related to the assumed contingent arrangement (note 19) |
Concept (Monetary) |
For Period |
Debit |
vrna:UnwindingOfDiscountFactorRelatedToTheAssumedContingentArrangement |
| 593 |
Total finance expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 594 |
2428402 - Disclosure - Taxation - Disclosure of major components of tax expense (income) (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/TaxationDisclosureOfMajorComponentsOfTaxExpenseIncomeDetails |
| 595 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 596 |
Income Tax Authority, Name [Axis] |
Axis |
|
|
vrna:IncomeTaxAuthorityName1Axis |
| 597 |
Income Tax Authority, Name [Domain] |
Member |
|
|
vrna:IncomeTaxAuthorityName1Domain |
| 598 |
UK |
Member |
|
|
vrna:HerMajestysRevenueandCustomsHMRC1Member |
| 599 |
US |
Member |
|
|
vrna:UnitedStatesFederalTaxAuthorityMember |
| 600 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 601 |
Analysis of tax credit for the year |
Abstract |
|
|
ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract |
| 602 |
Current tax: |
Abstract |
|
|
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract |
| 603 |
U.K. tax credit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncome |
| 604 |
Adjustment in respect of prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 605 |
Total tax credit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods |
| 606 |
Factors affecting the tax credit for the year |
Abstract |
|
|
ifrs-full:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract |
| 607 |
Loss on ordinary activities before taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AccountingProfit |
| 608 |
Multiplied by standard rate of corporation tax of 19% (2017: 19.25% and 2016: 20%) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxExpenseIncomeAtApplicableTaxRate |
| 609 |
Standard rate of corporation tax |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 610 |
Effects of: |
Abstract |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract |
| 611 |
Non-deductible expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss |
| 612 |
Fair value adjustment on derivative financial instruments |
Concept (Monetary) |
For Period |
Debit |
vrna:TaxEffectOfFairValueAdjustmentOnDerivativeInstrument |
| 613 |
Research and development incentive |
Concept (Monetary) |
For Period |
Debit |
vrna:TaxEffectOfTaxCreditResearchAndDevelopment |
| 614 |
Temporary differences not recognized |
Concept (Monetary) |
For Period |
Debit |
vrna:TaxEffectOfTimingDifferencesNotRecognized |
| 615 |
Difference in overseas tax rates |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfForeignTaxRates |
| 616 |
Tax losses carried forward not recognized |
Concept (Monetary) |
For Period |
Debit |
vrna:TaxEffectOfUnusedTaxLosses |
| 617 |
Adjustment in respect of prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 618 |
Total tax credit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 619 |
2428403 - Disclosure - Taxation - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/TaxationNarrativeDetails |
| 620 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 621 |
Income Tax Authority, Name [Axis] |
Axis |
|
|
vrna:IncomeTaxAuthorityName1Axis |
| 622 |
Income Tax Authority, Name [Domain] |
Member |
|
|
vrna:IncomeTaxAuthorityName1Domain |
| 623 |
U.S. federal tax |
Member |
|
|
vrna:UnitedStatesFederalTaxAuthorityMember |
| 624 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 625 |
Standard rate of corporation tax |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 626 |
Unrecognized deferred tax asset percent |
Concept (Percent) |
For Period |
|
vrna:ApplicableTaxRateforUnrecognisedDeferredTaxAssets |
| 627 |
Unrecognized deferred tax asset |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates |
| 628 |
2428404 - Disclosure - Taxation - Disclosure of temporary difference, unused tax losses and unused tax credits (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/TaxationDisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDetails |
| 629 |
Implied Table |
Table |
* |
* |
implied:Table |
| 630 |
Disclosure of income tax [Abstract] |
Abstract |
|
|
vrna:DisclosureofincometaxAbstract |
| 631 |
Deferred tax assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssets |
| 632 |
Deferred tax liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilities |
| 633 |
Net balances |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilityAsset |
| 634 |
2431402 - Disclosure - Goodwill (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/GoodwillDetails |
| 635 |
Implied Table |
Table |
* |
* |
implied:Table |
| 636 |
Disclosure of detailed information about intangible assets [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 637 |
Goodwill at January 1 and December 31 |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 638 |
Market capitalization |
Concept (Monetary) |
As Of |
Debit |
vrna:MarketCapitalizationAmount |
| 639 |
Equity attributable to owners of parent |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 640 |
Impairment loss recognised in profit or loss, intangible assets other than goodwill |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 641 |
2434402 - Disclosure - Intangible assets - Disclosure of reconciliation of changes in intangible assets and goodwill (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/IntangibleAssetsDisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillDetails |
| 642 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 643 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 644 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 645 |
IP R&D |
Member |
|
|
vrna:InProcessResearchAndDevelopment1Member |
| 646 |
Computer software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 647 |
Patents |
Member |
|
|
ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember |
| 648 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 649 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 650 |
Cost |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 651 |
Accumulated depreciation |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 652 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 653 |
Beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 654 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill |
| 655 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill |
| 656 |
Charge for year |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 657 |
Ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 658 |
2434403 - Disclosure - Intangible assets - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/IntangibleAssetsNarrativeDetails |
| 659 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 660 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 661 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 662 |
Patents |
Member |
|
|
ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember |
| 663 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 664 |
Amortization period |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillPeriod |
| 665 |
Market capitalization |
Concept (Monetary) |
As Of |
Debit |
vrna:MarketCapitalizationAmount |
| 666 |
Net assets |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 667 |
Impairment |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 668 |
2437402 - Disclosure - Property, plant and equipment (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/PropertyPlantAndEquipmentDetails |
| 669 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 670 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 671 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 672 |
Computer hardware |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 673 |
Office equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 674 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 675 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 676 |
Cost |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 677 |
Accumulated depreciation |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 678 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 679 |
Cost |
Abstract |
|
|
ifrs-full:ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract |
| 680 |
Property, plant and equipment beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 681 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment |
| 682 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 683 |
Property, plant and equipment ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 684 |
Accumulated depreciation |
Abstract |
|
|
vrna:AccumulatedDepreciationAbstract |
| 685 |
Property, plant and equipment beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 686 |
Charge for the year |
Concept (Monetary) |
For Period |
|
ifrs-full:DepreciationPropertyPlantAndEquipment |
| 687 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 688 |
Property, plant and equipment ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 689 |
Net book value |
Abstract |
|
|
vrna:NetBookValueAbstract |
| 690 |
Property plant and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 691 |
2440402 - Disclosure - Prepayments and other receivables (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/PrepaymentsAndOtherReceivablesDetails |
| 692 |
Implied Table |
Table |
* |
* |
implied:Table |
| 693 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 694 |
Prepayments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome |
| 695 |
Deferred IPO costs |
Concept (Monetary) |
As Of |
Debit |
vrna:CurrentPrepaymentsAndOtherCurrentAssetsDeferredIPOCosts |
| 696 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherCurrentReceivables |
| 697 |
Total prepayments and other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets |
| 698 |
2449402 - Disclosure - Share Capital - Movements in the Company's share capital (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareCapitalMovementsInCompanysShareCapitalDetails |
| 699 |
Implied Table |
Table |
* |
* |
implied:Table |
| 700 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 701 |
Number of shares |
Abstract |
|
|
ifrs-full:ReconciliationOfNumberOfSharesOutstandingAbstract |
| 702 |
Beginning balance (in shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesOutstanding |
| 703 |
Issuance of shares (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 704 |
Exercise of options (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 705 |
Ending balance (in shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesOutstanding |
| 706 |
Share Capital amounts in Ł'000s |
Abstract |
|
|
vrna:ReconciliationOfValueOfSharesOutstandingRollForward |
| 707 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
vrna:ValueOfSharesOutstanding |
| 708 |
Issuance of shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 709 |
Exercise of options |
Concept (Monetary) |
For Period |
Credit |
vrna:ValueOfSharesExercised |
| 710 |
Vesting of RSUs |
Concept (Monetary) |
For Period |
Credit |
vrna:ValueOfRestrictedStockUnitsVested |
| 711 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
vrna:ValueOfSharesOutstanding |
| 712 |
2449403 - Disclosure - Share Capital - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareCapitalNarrativeDetails |
| 713 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 714 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 715 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 716 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 717 |
Sale Of Stock [Axis] |
Axis |
|
|
vrna:SaleOfStockAxis |
| 718 |
Sale Of Stock [Domain] |
Member |
|
|
vrna:SaleOfStockDomain |
| 719 |
Global Offering |
Member |
|
|
vrna:GlobalOfferingMember |
| 720 |
IPO |
Member |
|
|
vrna:IPO1Member |
| 721 |
Private Placement |
Member |
|
|
vrna:PrivatePlacement1Member |
| 722 |
Over-Allotment Option |
Member |
|
|
vrna:OverAllotmentOption1Member |
| 723 |
Shareholder Private Placement |
Member |
|
|
vrna:ShareholderPrivatePlacementMember |
| 724 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 725 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 726 |
ADS |
Member |
|
|
vrna:AmericanDepositarySharesMember |
| 727 |
Ordinary shares |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 728 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 729 |
Consolidation of shares |
Concept (Pure) |
For Period |
|
vrna:StockholdersEquityNoteStockSplitConversionRatio2 |
| 730 |
Price per share (in pounds per share) |
Concept (Share) |
As Of |
|
ifrs-full:ParValuePerShare |
| 731 |
Number of shares authorized |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesAuthorised |
| 732 |
Share capital |
Concept (Monetary) |
As Of |
Credit |
vrna:ValueOfSharesAuthorized |
| 733 |
Number of shares allotted, unrestricted, called up and fully paid (in shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesOutstanding |
| 734 |
Number of ordinary shares in issue (in shares) |
Concept (Shares) |
As Of |
|
vrna:NumberOfSharesIssuedInOffering |
| 735 |
Shares issued price (in dollars or pounds per share) |
Concept (Share) |
As Of |
|
vrna:SaleofStockPricePerShare1 |
| 736 |
Gross proceeds from the April 2017 Global Offering |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 737 |
Finance expense from movements in exchange rates |
Concept (Monetary) |
For Period |
Debit |
vrna:ShareIssueRelatedCostMovementsInExchangeRates |
| 738 |
Saving on commission payable |
Concept (Monetary) |
For Period |
Credit |
vrna:ShareIssueRelatedCostReductionFromCommissionPayableSavings |
| 739 |
Finance expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 740 |
Number of shares subscribed from warrant maximum (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 741 |
Exercise price (pounds per share) |
Concept (Share) |
As Of |
|
vrna:ClassofWarrantorRightExercisePriceofWarrantsorRights1 |
| 742 |
Proceeds from warrant exercise |
Concept (Monetary) |
For Period |
Debit |
vrna:ProceedsfromWarrantExercises1 |
| 743 |
Number of ordinary shares (in shares) |
Concept (Integer) |
As Of |
|
vrna:NumberOfOrdinarySharesComprisingUnit |
| 744 |
Number warrants (in warrants) |
Concept (Integer) |
As Of |
|
vrna:NumberOfWarrantsComprisingUnit |
| 745 |
Number of shares subscribed (in shares) |
Concept (Shares) |
As Of |
|
vrna:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 |
| 746 |
Exercise price percent |
Concept (Percent) |
As Of |
|
vrna:ClassofWarrantorRightExercisePriceAsPercentOfPlacingPriceOfWarrants |
| 747 |
Gross proceeds from issue of shares and warrants |
Concept (Monetary) |
For Period |
Debit |
vrna:ProceedsFromIssuingSharesAndWarrants |
| 748 |
Number of shares issued (in shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 749 |
2452402 - Disclosure - Share-based payments charge - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeNarrativeDetails |
| 750 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 751 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 752 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 753 |
Incentive Award Plan 2017 |
Member |
|
|
vrna:IncentiveAwardPlan2017Member |
| 754 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 755 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 756 |
Advisor Options |
Member |
|
|
vrna:AdvisorMember |
| 757 |
Vesting1 [Axis] |
Axis |
|
|
vrna:Vesting1Axis |
| 758 |
Vesting1 [Domain] |
Member |
|
|
vrna:Vesting1Domain |
| 759 |
Method one, tranche one |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodOneTrancheOneMember |
| 760 |
Method one, tranche two |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodOneTrancheTwoMember |
| 761 |
Method one, tranche three |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodOneTrancheThreeMember |
| 762 |
Method two, tranche one |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodTwoTrancheOneMember |
| 763 |
Method two, tranche two |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodTwoTrancheTwoMember |
| 764 |
Method two, tranche three |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodTwoTrancheThreeMember |
| 765 |
Method two, tranche four |
Member |
|
|
vrna:SharebasedCompensationAwardVestingMethodTwoTrancheFourMember |
| 766 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 767 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 768 |
Bottom of range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 769 |
Top of range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 770 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 771 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 772 |
Unapproved Scheme |
Member |
|
|
vrna:UnapprovedShareOptionSchemeMember |
| 773 |
EMI |
Member |
|
|
vrna:EMIOptionSchemeMember |
| 774 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 775 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 776 |
Share-based payment charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 777 |
Vesting period |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod |
| 778 |
Number of vesting methods |
Concept (Integer) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingMethods |
| 779 |
Vesting portion |
Concept (Pure) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedPortion |
| 780 |
Exercise period |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:SharebasedCompensationArrangementbySharebasedPaymentAwardExpirationPeriod1 |
| 781 |
Hours worked per week (at least) |
Concept (Integer) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfHoursWorkedPerWeek |
| 782 |
Percent of working time (at least) |
Concept (Percent) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfWorkTimeRequired |
| 783 |
Number of share options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 784 |
Fair value of equity instruments |
Concept (Monetary) |
For Period |
Debit |
vrna:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValue |
| 785 |
Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement |
| 786 |
Weighted average remaining contractual life of outstanding share options |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 787 |
Granted, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 788 |
2452403 - Disclosure - Share-based payments charge - Disclosure of indirect measurement of fair value of goods or services received, share options granted during period (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeDisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodDetails |
| 789 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 790 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 791 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 792 |
Bottom of range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 793 |
Top of range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 794 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 795 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 796 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 797 |
Unapproved Scheme |
Member |
|
|
vrna:UnapprovedShareOptionSchemeMember |
| 798 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 799 |
Options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 800 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 801 |
Expected life of options |
Concept (Decimal) |
For Period |
|
ifrs-full:DescriptionOfOptionLifeShareOptionsGranted |
| 802 |
Annualized volatility |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 803 |
Dividend rate |
Concept (Percent) |
For Period |
|
ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted |
| 804 |
Vesting period |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod |
| 805 |
2452404 - Disclosure - Share-based payments charge - Share options movements (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeShareOptionsMovementsDetails |
| 806 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 807 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 808 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 809 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 810 |
EMI |
Member |
|
|
vrna:EMIOptionSchemeMember |
| 811 |
Grant Issue And Expiry [Axis] |
Axis |
|
|
vrna:GrantIssueAndExpiryAxis |
| 812 |
Grant Issue And Expiry [Domain] |
Member |
|
|
vrna:GrantIssueAndExpiryDomain |
| 813 |
Year Of Issue, 2012, Expiry Date June 1, 2022 |
Member |
|
|
vrna:YearOfIssue2012ExpiryDateJune12022Member |
| 814 |
Year Of Issue, 2013, Expiry Date April 15, 2023 |
Member |
|
|
vrna:YearOfIssue2013ExpiryDateApril152023Member |
| 815 |
Year Of Issue, 2013, Expiry Date June 1, 2023 |
Member |
|
|
vrna:YearOfIssue2013ExpiryDateJune12023Member |
| 816 |
Year Of Issue, 2013, Expiry Date July 29, 2023 |
Member |
|
|
vrna:YearOfIssue2013ExpiryDateJuly292023Member |
| 817 |
Year Of Issue, 2014, Expiry Date May 15, 2024 |
Member |
|
|
vrna:YearOfIssue2014ExpiryDateMay152024Member |
| 818 |
Year Of Issue, 2014, Expiry Date August 6, 2018 |
Member |
|
|
vrna:YearOfIssue2014ExpiryDateAugust62018Member |
| 819 |
Year Of Issue, 2015, Expiry Date January 29, 2025 |
Member |
|
|
vrna:YearOfIssue2015ExpiryDateJanuary292025Member |
| 820 |
Year Of Issue, 2016, Expiry Date February 2, 2026 |
Member |
|
|
vrna:YearOfIssue2016ExpiryDateFebruary22026Member |
| 821 |
Year Of Issue, 2016, Expiry Date August 3, 2026 |
Member |
|
|
vrna:YearOfIssue2016ExpiryDateAugust32026Member |
| 822 |
Year Of Issue, 2016, Expiry Date September 13, 2026 |
Member |
|
|
vrna:YearOfIssue2016ExpiryDateSeptember132026Member |
| 823 |
Year Of Issue, 2016, Expiry Date September 16, 2026 |
Member |
|
|
vrna:YearOfIssue2016ExpiryDateSeptember162026Member |
| 824 |
Year Of Issue, 2017, Expiry Date April 26, 2027 |
Member |
|
|
vrna:YearOfIssue2017ExpiryDateApril262027Member |
| 825 |
Year Of Issue, 2018, Expiry Date March 9, 2028 |
Member |
|
|
vrna:YearOfIssue2018ExpiryDateMarch82028MemberDomain |
| 826 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 827 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 828 |
Bottom of range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 829 |
Top of range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 830 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 831 |
Number of other equity instruments exercised or vested in share-based payment arrangement |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement |
| 832 |
Exercise of options |
Concept (Monetary) |
As Of |
|
ifrs-full:ExercisePriceOfOutstandingShareOptions |
| 833 |
Beginning balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 834 |
Options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 835 |
Options exercised (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 836 |
Options forfeited (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 837 |
Options expired (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 838 |
Ending balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 839 |
2452405 - Disclosure - Share-based payments charge - Disclosure of number and weighted average exercise prices of other equity instruments (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeDisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsDetails |
| 840 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 841 |
Grant Issue And Expiry [Axis] |
Axis |
|
|
vrna:GrantIssueAndExpiryAxis |
| 842 |
Grant Issue And Expiry [Domain] |
Member |
|
|
vrna:GrantIssueAndExpiryDomain |
| 843 |
Year Of Issue, 2017, Expiry Date April 26, 2027 |
Member |
|
|
vrna:YearOfIssue2017ExpiryDateApril262027Member |
| 844 |
Year Of Issue, 2018, Expiry Date March 8, 2028 |
Member |
|
|
vrna:YearOfIssue2018ExpiryDateMarch82028MemberDomain |
| 845 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 846 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 847 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 848 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 849 |
Beginning balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 850 |
Options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted |
| 851 |
Options exercised (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement |
| 852 |
Options forfeited (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement |
| 853 |
Options expired (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement |
| 854 |
Ending balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 855 |
2452407 - Disclosure - Share-based payments charge - Outstanding and exercisable share options by scheme (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeOutstandingAndExercisableShareOptionsBySchemeDetails |
| 856 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 857 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 858 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 859 |
Unapproved Scheme |
Member |
|
|
vrna:UnapprovedShareOptionSchemeMember |
| 860 |
EMI |
Member |
|
|
vrna:EMIOptionSchemeMember |
| 861 |
Unapproved And EMI Share Option Schemes |
Member |
|
|
vrna:UnapprovedAndEMIShareOptionSchemesMember |
| 862 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 863 |
Outstanding (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 864 |
Exercisable (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 865 |
Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 866 |
Weighted average exercise price in Ł for Exercisable (pounds per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 867 |
2452408 - Disclosure - Share-based payments charge - Number of options granted, expired and the weighted average exercise price of options (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeNumberOfOptionsGrantedExpiredAndWeightedAverageExercisePriceOfOptionsDetails |
| 868 |
Disclosure of number and weighted average remaining contractual life of outstanding share options [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable |
| 869 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 870 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 871 |
Employees |
Member |
|
|
vrna:EmployeeMember |
| 872 |
Directors |
Member |
|
|
ifrs-full:KeyManagementPersonnelOfEntityOrParentMember |
| 873 |
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems |
| 874 |
Beginning balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 875 |
Options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 876 |
Options exercised (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 877 |
Options forfeited (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 878 |
Options expired (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 879 |
Ending balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 880 |
Exercisable (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 881 |
Beginning balance, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 882 |
Granted, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 883 |
Exercised, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 884 |
Forfeited, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 885 |
Expired, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 886 |
Ending balance, Weighted average exercise price in Ł for Outstanding (pounds per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 887 |
Weighted average exercise price in Ł for Exercisable (pounds per share) |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 888 |
2452409 - Disclosure - Share-based payments charge - Equity instruments other than options granted (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/ShareBasedPaymentsChargeEquityInstrumentsOtherThanOptionsGrantedDetails |
| 889 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 890 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 891 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 892 |
Employees |
Member |
|
|
vrna:EmployeeMember |
| 893 |
Directors |
Member |
|
|
ifrs-full:KeyManagementPersonnelOfEntityOrParentMember |
| 894 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 895 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 896 |
Restricted Stock Units |
Member |
|
|
vrna:RestrictedStockUnitsMember |
| 897 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 898 |
Beginning balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 899 |
Options granted (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted |
| 900 |
Ending balance (in shares) |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 901 |
Number of other equity instruments exercised or vested in share-based payment arrangement |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement |
| 902 |
Restricted stock units forfeited (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement |
| 903 |
2455402 - Disclosure - Trade and other payables (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/TradeAndOtherPayablesDetails |
| 904 |
Implied Table |
Table |
* |
* |
implied:Table |
| 905 |
Subclassifications of assets, liabilities and equities [abstract] |
Abstract |
|
|
ifrs-full:SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract |
| 906 |
Trade payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayablesToTradeSuppliers |
| 907 |
Other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentPayables |
| 908 |
Accruals |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AccrualsClassifiedAsCurrent |
| 909 |
Total trade and other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 910 |
Accruals related to offering expenses |
Concept (Monetary) |
As Of |
Credit |
vrna:AccrualsClassifiedAsCurrentOfferingExpense |
| 911 |
2458402 - Disclosure - Assumed contingent obligation related to the business combination - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AssumedContingentObligationRelatedToBusinessCombinationNarrativeDetails |
| 912 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 913 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 914 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 915 |
Rhinopharma Limited |
Member |
|
|
vrna:RhinopharmaLimitedMember |
| 916 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 917 |
Assumed contingent obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 918 |
Increase in value of the assumed contingent obligation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination |
| 919 |
Discount percent |
Concept (Percent) |
For Period |
|
vrna:DiscountRateAppliedToContingentObligation |
| 920 |
Reported change to the value of the liability |
Concept (Monetary) |
For Period |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationImpactOfReasonablyPossibleReductionInAssumedDiscountRate |
| 921 |
2458403 - Disclosure - Assumed contingent obligation related to the business combination - Reconciliation of changes in contingent liabilities (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AssumedContingentObligationRelatedToBusinessCombinationReconciliationOfChangesInContingentLiabilitiesDetails |
| 922 |
Implied Table |
Table |
* |
* |
implied:Table |
| 923 |
Disclosure of other provisions, contingent liabilities and contingent assets [Abstract] |
Abstract |
|
|
vrna:DisclosureofotherprovisionscontingentliabilitiesandcontingentassetsAbstract |
| 924 |
Reconciliation of changes in contingent liabilities recognised in business combination [abstract] |
Abstract |
|
|
ifrs-full:ReconciliationOfChangesInContingentLiabilitiesRecognisedInBusinessCombinationAbstract |
| 925 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 926 |
Re-measurement of assumed contingent obligation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInExistingLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination |
| 927 |
Impact of changes in foreign exchange rates |
Concept (Monetary) |
For Period |
Credit |
vrna:IncreaseDecreaseThroughChangeInExchangeRateContingentLiabilitiesRecognisedInBusinessCombination |
| 928 |
Unwinding of discount factor |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseThroughAdjustmentsArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination |
| 929 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 930 |
2458404 - Disclosure - Assumed contingent obligation related to the business combination - Reported change to the value of the liability (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/AssumedContingentObligationRelatedToBusinessCombinationReportedChangeToValueOfLiabilityDetails |
| 931 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 932 |
Valuation techniques used in fair value measurement [axis] |
Axis |
|
|
ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis |
| 933 |
Valuation techniques [member] |
Member |
|
|
ifrs-full:ValuationTechniquesMember |
| 934 |
Discount Rate, 1% Variable |
Member |
|
|
vrna:DiscountRate1VariableMember |
| 935 |
Revenue Concentration Risk, 10% Variable |
Member |
|
|
vrna:RevenueConcentrationRisk10VariableMember |
| 936 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 937 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 938 |
Rhinopharma Limited |
Member |
|
|
vrna:RhinopharmaLimitedMember |
| 939 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 940 |
Contingent liabilities recognised in business combination, variable up |
Concept (Monetary) |
As Of |
Credit |
vrna:Contingentliabilitiesrecognisedinbusinesscombinationvariableup |
| 941 |
Assumed contingent obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 942 |
Change in value of the assumed contingent obligation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination |
| 943 |
Contingent liabilities recognised in business combination, variable down |
Concept (Monetary) |
As Of |
Credit |
vrna:Contingentliabilitiesrecognisedinbusinesscombinationvariabledown |
| 944 |
Revenue assumption, % lower |
Concept (Percent) |
For Period |
|
vrna:PercentageOfReasonablyPossibleDecreaseInRevenueAssumptionForContingentLiabilitiesRecognisedInBusinessCombination |
| 945 |
Revenue assumption, % higher |
Concept (Percent) |
For Period |
|
vrna:PercentageOfReasonablyPossibleIncreaseInRevenueAssumptionForContingentLiabilitiesRecognisedInBusinessCombination |
| 946 |
Risk assumption, % lower |
Concept (Percent) |
For Period |
|
vrna:PercentageOfReasonablyPossibleDecreaseInRiskAssumptionForContingentLiabilitiesRecognisedInBusinessCombination |
| 947 |
Risk assumption, % higher |
Concept (Percent) |
For Period |
|
vrna:PercentageOfReasonablyPossibleIncreaseInRiskAssumptionForContingentLiabilitiesRecognisedInBusinessCombination |
| 948 |
2461402 - Disclosure - Warrants - Narrative (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/WarrantsNarrativeDetails |
| 949 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 950 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 951 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 952 |
Warrants |
Member |
|
|
vrna:Warrant1Member |
| 953 |
Ordinary shares |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 954 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 955 |
Number of units issued (in shares) |
Concept (Shares) |
As Of |
|
vrna:NumberOfSharesIssuedInOffering |
| 956 |
Placing price (in pounds per unit) |
Concept (Share) |
As Of |
|
vrna:SaleofStockPricePerShare1 |
| 957 |
Number of ordinary shares (in shares) |
Concept (Integer) |
As Of |
|
vrna:NumberOfOrdinarySharesComprisingUnit |
| 958 |
Number warrants (in warrants) |
Concept (Integer) |
As Of |
|
vrna:NumberOfWarrantsComprisingUnit |
| 959 |
Number of shares subscribed (in shares) |
Concept (Shares) |
As Of |
|
vrna:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 |
| 960 |
Exercise price percent |
Concept (Percent) |
As Of |
|
vrna:ClassofWarrantorRightExercisePriceAsPercentOfPlacingPriceOfWarrants |
| 961 |
Exercise price (pounds per share) |
Concept (Share) |
As Of |
|
vrna:ClassofWarrantorRightExercisePriceofWarrantsorRights1 |
| 962 |
Number of shares subscribed from warrant maximum (in shares) |
Concept (Shares) |
As Of |
|
vrna:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 963 |
Change in fair value |
Concept (Monetary) |
For Period |
Credit |
vrna:WarrantsandRightsIssuedDuringPeriod |
| 964 |
Warrant proceeds |
Concept (Monetary) |
For Period |
Debit |
vrna:ProceedsfromIssuanceofWarrants1 |
| 965 |
Transaction costs allocated to the issue of warrants (note 19) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 966 |
Warrants forfeited (in shares) |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 967 |
Consolidation of shares |
Concept (Pure) |
For Period |
|
vrna:StockholdersEquityNoteStockSplitConversionRatio2 |
| 968 |
Exercise price (pence per share) |
Concept (Share) |
As Of |
|
vrna:SharesIssuedExercisePricePerShare |
| 969 |
Fair value warrant |
Concept (Monetary) |
As Of |
Credit |
vrna:WarrantsandRightsOutstanding1 |
| 970 |
Variance recorded |
Concept (Monetary) |
For Period |
Credit |
vrna:FairValueAdjustmentofWarrants1 |
| 971 |
2461403 - Disclosure - Warrants - Assumptions in applying the Black-Scholes model, fair value warrants (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/WarrantsAssumptionsInApplyingBlackScholesModelFairValueWarrantsDetails |
| 972 |
Disclosure of classes of share capital [table] |
Table |
* |
* |
ifrs-full:DisclosureOfClassesOfShareCapitalTable |
| 973 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 974 |
Share Capital |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 975 |
Warrants |
Member |
|
|
vrna:Warrant1Member |
| 976 |
Disclosure of classes of share capital [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfClassesOfShareCapitalLineItems |
| 977 |
Warrants (in shares) |
Concept (Shares) |
As Of |
|
vrna:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 |
| 978 |
Exercise price (pounds per share) |
Concept (Share) |
As Of |
|
vrna:ClassofWarrantorRightExercisePriceofWarrantsorRights1 |
| 979 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
vrna:RiskFreeInterestRateOtherEquityInstrumentsGranted |
| 980 |
Expected term to exercise |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted |
| 981 |
Annualized volatility |
Concept (Percent) |
For Period |
|
vrna:ExpectedVolatilityOtherEquityInstrumentsGranted |
| 982 |
Dividend rate |
Concept (Percent) |
For Period |
|
vrna:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted |
| 983 |
2461404 - Disclosure - Warrants - Fair value adjustments (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/WarrantsFairValueAdjustmentsDetails |
| 984 |
Implied Table |
Table |
* |
* |
implied:Table |
| 985 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 986 |
Reconciliation Of Changes in Warrants Outstanding [Roll Forward] |
Abstract |
|
|
vrna:ReconciliationOfChangesinWarrantsOutstandingRollForward |
| 987 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
vrna:WarrantsandRightsOutstanding1 |
| 988 |
Fair value adjustments recognized in loss |
Concept (Monetary) |
For Period |
Debit |
vrna:FairValueAdjustmentofWarrantsExpense |
| 989 |
Fair value adjustments recognized in profit |
Concept (Monetary) |
For Period |
Credit |
vrna:FairValueAdjustmentofWarrantsIncome |
| 990 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
vrna:WarrantsandRightsOutstanding1 |
| 991 |
2461405 - Disclosure - Warrants - Effect when underlying parameters deviate (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/WarrantsEffectWhenUnderlyingParametersDeviateDetails |
| 992 |
Implied Table |
Table |
* |
* |
implied:Table |
| 993 |
Disclosure of share capital, reserves and other equity interest [Abstract] |
Abstract |
|
|
vrna:DisclosureofsharecapitalreservesandotherequityinterestAbstract |
| 994 |
Variable up, Volatility (up / down 10% pts) |
Concept (Monetary) |
As Of |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationWarrantsandRightsOutstandingVolatilityVariableUp |
| 995 |
Base case, Volatility (up / down 10% pts) |
Concept (Monetary) |
As Of |
Credit |
vrna:WarrantsandRightsOutstanding1 |
| 996 |
Variable down, Volatility (up / down 10% pts) |
Concept (Monetary) |
As Of |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationWarrantsandRightsOutstandingVolatilityVariableDown |
| 997 |
Variable up, Time to maturity (up / down 6 months) |
Concept (Monetary) |
As Of |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationWarrantsandRightsOutstandingTimeToMaturityVariableUp |
| 998 |
Variable down, Time to maturity (up / down 6 months) |
Concept (Monetary) |
As Of |
Credit |
vrna:SensitivityAnalysisOfFairValueContingentLiabilitiesRecognisedInBusinessCombinationWarrantsandRightsOutstandingTimeToMaturityVariableDown |
| 999 |
Volatility (up/down), percentage |
Concept (Percent) |
For Period |
|
vrna:WarrantsandRightsOutstandingFairValueAdjustmentofWarrantsVolatilityDeviationPercent |
| 1000 |
Time to maturity (up, down), months |
Concept (xbrli:durationItemType) |
For Period |
|
vrna:WarrantsandRightsOutstandingFairValueAdjustmentofWarrantsTimeToMaturityDeviationPeriod |
| 1001 |
2464402 - Disclosure - Financial commitments (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/FinancialCommitmentsDetails |
| 1002 |
Disclosure of finance lease and operating lease by lessee [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable |
| 1003 |
Classes of assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfAssetsAxis |
| 1004 |
Assets [member] |
Member |
|
|
ifrs-full:ClassesOfAssetsMember |
| 1005 |
Land and Buildings |
Member |
|
|
ifrs-full:LandAndBuildingsMember |
| 1006 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 1007 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 1008 |
Within one year |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 1009 |
Between one and five years |
Member |
|
|
ifrs-full:LaterThanOneYearMember |
| 1010 |
Disclosure of finance lease and operating lease by lessee [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems |
| 1011 |
Operating lease obligations: |
Abstract |
|
|
ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract |
| 1012 |
Minimum lease payments payable under non-cancellable operating lease |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease |
| 1013 |
2467401 - Disclosure - Related parties transactions and other shareholder matters (Details) |
Network |
* |
* |
http://www.veronapharma.com/role/RelatedPartiesTransactionsAndOtherShareholderMattersDetails |
| 1014 |
Disclosure of transactions between related parties [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable |
| 1015 |
Counterparties [axis] |
Axis |
|
|
ifrs-full:CounterpartiesAxis |
| 1016 |
Counterparties [member] |
Member |
|
|
ifrs-full:CounterpartiesMember |
| 1017 |
Vivo Capital, OrbiMed And Abingworth |
Member |
|
|
vrna:VivoCapitalOrbiMedAndAbingworthMember |
| 1018 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1019 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1020 |
Entities with joint control or significant influence over entity |
Member |
|
|
ifrs-full:JointControlOrSignificantInfluenceMember |
| 1021 |
Chief executive officer |
Member |
|
|
vrna:ChiefExecutiveOfficerMember |
| 1022 |
Chairman |
Member |
|
|
vrna:ChairmanMember |
| 1023 |
Non-executive director |
Member |
|
|
vrna:NonExecutiveDirectorMember |
| 1024 |
Key management personnel of entity or parent |
Member |
|
|
ifrs-full:KeyManagementPersonnelOfEntityOrParentMember |
| 1025 |
Disclosure of transactions between related parties [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems |
| 1026 |
Percent of issued ordinary shares |
Concept (Percent) |
For Period |
|
vrna:DirectorAppointmentRightsMinimumOwnershipPercentageForRelatedPartyToRetainRights |
| 1027 |
Number of ordinary shares purchased in related party transaction (in shares) |
Concept (Shares) |
For Period |
|
vrna:OrdinarySharesPurchasedSharesRelatedParty |
| 1028 |
Amount of ordinary shares purchased in related party transaction |
Concept (Monetary) |
For Period |
Debit |
vrna:OrdinarySharesPurchasedAmountRelatedPartyTransaction |
| 1029 |
Amounts receivable, related party transactions |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:AmountsReceivableRelatedPartyTransactions |
| 1030 |
Consultancy services provided |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity |